94 related articles for article (PubMed ID: 1987896)
1. [Clinical effects of stearyl-ara-CMP (YNK-01) on chronic hematologic malignancies].
Im T; Ota K; Ohira H; Yasui Y; Nakao Y; Furukawa Y; Inoue K; Yamane T; Hiyoshi M; Kishida T
Gan To Kagaku Ryoho; 1991 Jan; 18(1):139-42. PubMed ID: 1987896
[No Abstract] [Full Text] [Related]
2. [Pharmacokinetics of stearyl-ara-CMP (YNK-01) in patients with hematologic neoplasms].
Ueda T; Kamiya K; Tanaka T; Tsutani H; Wano Y; Sugiyama M; Nakamura T
Gan To Kagaku Ryoho; 1989 Sep; 16(9):3303-6. PubMed ID: 2782923
[No Abstract] [Full Text] [Related]
3. [A case of complete remission from acute unclassified leukemia achieved by using a prodrug of ara C, stearyl-ara-CMP (YNK01)].
Nishikawa M; Morita K; Komada F; Uemura Y; Kageyama S; Minami N; Deguchi K; Shirakawa S
Gan No Rinsho; 1990 Oct; 36(12):2204-9. PubMed ID: 2232191
[TBL] [Abstract][Full Text] [Related]
4. [Successful treatment of myelodysplastic syndrome with cytarabine ocfosfate].
Arai T; Narimiya S; Hayakawa K; Takaya T; Toshima S; Araki M; Uchida A; Yoshimi N; Shibuya C; Yasuda Y
Gan To Kagaku Ryoho; 1994 Jun; 21(7):1085-8. PubMed ID: 8002627
[No Abstract] [Full Text] [Related]
5. [Phase II study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) on hematological malignancies].
Tatsumi N; Yamada K; Ohshima T; Nakamura T; Ohno R; Masaoka T; Kimura I; Kimura K
Gan To Kagaku Ryoho; 1990 Dec; 17(12):2387-95. PubMed ID: 2260876
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
[TBL] [Abstract][Full Text] [Related]
7. [Successful treatment of acute myelomonocytic leukemia developed from MDS with cytarabine ocfosfate (SPAC)].
Wake A; Takazawa A; Serino Y; Tonai S; Nakanishi M; Murakami S; Ogawa R; Nagata K; Mori N; Nakata K
Gan To Kagaku Ryoho; 1995 Feb; 22(3):395-8. PubMed ID: 7880111
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of myelodysplastic syndrome with 1-beta-D-arabinofuranosylcytosine 5'-stearylphosphate.
Ueda T; Imamura S; Kawai Y; Wano Y; Kamiya K; Tsutani H; Nakamura T
Leuk Res; 1990; 14(11-12):1067-8. PubMed ID: 2280605
[No Abstract] [Full Text] [Related]
9. [Phase I study of YNK01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate)].
Fukuoka M; Miyazaki T; Yoshida Y; Hattori M; Niitani H; Nakamura T; Hirota Y; Ohta K; Tanaka M; Suzuoki Y
Gan To Kagaku Ryoho; 1990 Nov; 17(11):2213-9. PubMed ID: 2241185
[TBL] [Abstract][Full Text] [Related]
10. [Late phase II study of YNK-01 (an oral prodrug of cytarabine) for hepatocellular carcinoma].
Suto T; Yoshida Y; Sakata Y; Ono T; Yoshida T; Yamada N; Chida N; Oohira H
Gan To Kagaku Ryoho; 1998 Oct; 25(12):1933-8. PubMed ID: 9797816
[TBL] [Abstract][Full Text] [Related]
11. [Clinical efficacy of YNK 01 (1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate) in patients with polycythemia vera].
Naito K; Kitaori K; Morishima Y
Gan To Kagaku Ryoho; 1993 May; 20(7):973-6. PubMed ID: 8489306
[No Abstract] [Full Text] [Related]
12. Interferon alpha plus intermittent oral Ara-C ocfosfate (YNK-01) in chronic myeloid leukemia primarily resistant or with minimal cytogenetic response to interferon.
Cervantes F; Sureda A; Hernández-Boluda JC; Martino R; Brunet S; Borrego D; Antich JL; Montserrat E
Haematologica; 2001 Dec; 86(12):1281-6. PubMed ID: 11726320
[TBL] [Abstract][Full Text] [Related]
13. Treatment of myelodysplastic syndromes with orally administered 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate.
Ohno R; Tatsumi N; Hirano M; Imai K; Mizoguchi H; Nakamura T; Kosaka M; Takatsuki K; Yamaya T; Toyama K
Oncology; 1991; 48(6):451-5. PubMed ID: 1749580
[TBL] [Abstract][Full Text] [Related]
14. [A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies].
Ueda Y; Mori S; Ito T; Maesako Y; Konishi H; Yagiri Y
Rinsho Ketsueki; 1998 May; 39(5):348-54. PubMed ID: 9637884
[TBL] [Abstract][Full Text] [Related]
15. A severe hepatic disorder with myelodysplastic syndrome, treated with cytarabine ocfosfate, in a dog.
Ide K; Momoi Y; Minegishi M; Sekiguchi M; Konno K; Iwasaki T
Aust Vet J; 2003; 81(1-2):47-9. PubMed ID: 15084010
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of refractory hematologic malignancies by combination of cytarabine ocfosfate and etoposide].
Kiyama Y; Suzuki G; Masauzi N; Ohizumi H; Kobayashi N; Ogasawara M; Naohara T; Saito M; Higa T; Kasai M
Gan To Kagaku Ryoho; 1996 Oct; 23(12):1717-20. PubMed ID: 8886052
[TBL] [Abstract][Full Text] [Related]
17. [Five cases of myelodysplastic syndrome treated with cytarabine ocfosfate].
Nishi T; Funasako M; Hata N; Andoh K; Itoh Y; Ono H; Itoh K; Sato Y; Sato H; Taniji M; Nakai S; Ueda A; Fujimoto H; Ohata M
Gan To Kagaku Ryoho; 1996 Sep; 23(10):1331-4. PubMed ID: 8831748
[TBL] [Abstract][Full Text] [Related]
18. [Effects of cytarabine ocfosfate on colony-stimulating factor in myelodysplastic syndrome with monosomy 7].
Masumoto A; Ohbayashi Y; Kawada H; Arimori K; Sasao T; Ogawa Y; Fujiwara H; Fukuda R; Watanabe S; Umeda Y
Rinsho Ketsueki; 1994 Jun; 35(6):603-8. PubMed ID: 7521405
[TBL] [Abstract][Full Text] [Related]
19. Persistent molecular remission of refractory acute myeloid leukemia with inv(16)(p13.1q22) in an elderly patient induced by cytarabine ocfosfate hydrate.
Arahata M; Shimizu Y; Asakura H; Nakao S
J Hematol Oncol; 2015 Feb; 8():5. PubMed ID: 25652695
[TBL] [Abstract][Full Text] [Related]
20. [Effectiveness of low dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes--analysis of factors influencing the duration of responses, survival and clinical effects].
Sawada H; Abe T; Akasaka K; Ishikura H; Izumi Y; Inamoto Y; Usui T; Okazaki T; Okada H; Katoh Y
Rinsho Ketsueki; 1987 Sep; 28(9):1553-60. PubMed ID: 3437517
[No Abstract] [Full Text] [Related]
[Next] [New Search]
